SELETALISIB

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C23H14ClF3N6O
Molecular Weight	482.845
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[O-][N+]1=CC=CC(=C1)C2=C(C=C3C=CC=C(Cl)C3=N2)[C@@H](NC4=C5N=CC=CC5=NC=N4)C(F)(F)F

InChI

InChIKey=LNLJHGXOFYUARS-OAQYLSRUSA-N

InChI=1S/C23H14ClF3N6O/c24-16-6-1-4-13-10-15(18(31-19(13)16)14-5-3-9-33(34)11-14)21(23(25,26)27)32-22-20-17(29-12-30-22)7-2-8-28-20/h1-12,21H,(H,29,30,32)/t21-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C23H14ClF3N6O
Molecular Weight	482.845
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28442583 | https://www.ncbi.nlm.nih.gov/pubmed/28160012 | http://adisinsight.springer.com/drugs/800039987 | https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-005541-30/DE

Seletalisib (UCB-5857) is a potent, ATP-competitive, and selective phosphoinositide 3-kinase (PI3K) delta inhibitor. Findings from cellular assays of adaptive immunity demonstrated that seletalisib blocks human T-cell production of several cytokines from activated T-cells. Additionally, seletalisib inhibited B-cell proliferation and cytokine release. In human whole blood assays, seletalisib inhibited CD69 expression upon B-cell activation and anti-IgE-mediated basophil degranulation. Seletalisib safety, tolerability and pharmacokinetic/pharmacodynamic profiles support its continued clinical development in immune-inflammatory diseases. UCB Pharma is developing Seletalisib for the treatment of immune and inflammatory diseases including Activated PI3K delta Syndrome (APDS), Sjogren's syndrome and psoriasis.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
PI3-kinase p110-delta subunit 43 Target ID: CHEMBL3130 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28442583	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Activated PI3K delta syndrome 1 Sources: https://www.ucb.com/our-science/Our-clinical-studies/UCB5857	Primary	Phase III 665	Unknown Approved Use Unknown
Sjogren's syndrome 8 Sources: http://adisinsight.springer.com/drugs/800039987	Primary	Phase II 1147	Unknown Approved Use Unknown
Psoriasis 87 Sources: http://adisinsight.springer.com/drugs/800039987	Primary	Phase I 438	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
690.8 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28160012	45 mg single, oral dose: 45 mg route of administration: Oral experiment type: SINGLE co-administered:		SELETALISIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1114 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28160012	45 mg 1 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		SELETALISIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
17252 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28160012	45 mg single, oral dose: 45 mg route of administration: Oral experiment type: SINGLE co-administered:		SELETALISIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
16963 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28160012	45 mg 1 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		SELETALISIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
22.4 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28160012	45 mg single, oral dose: 45 mg route of administration: Oral experiment type: SINGLE co-administered:		SELETALISIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
28.5 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28160012	45 mg 1 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		SELETALISIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	P-gp 2052 MATE1 182 MATE2-K 33 OAT1 395 OAT3 391 BCRP 697 OATP1B1 503 BSEP 63 MRP2 252 OATP1B3 435 OCT1 393 OCT2 434

Drug as victim

Target	Modality	Activity
BSEP 63	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/31678424/	no
MATE1 182	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/31678424/	no
MATE2-K 33	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/31678424/	no
MRP2 252	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/31678424/	no
OAT1 395	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/31678424/	no
OAT3 391	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/31678424/	no
OATP1B1 503	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/31678424/	no
OATP1B3 435	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/31678424/	no
OCT1 393	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/31678424/	no
OCT2 434	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/31678424/	no
P-gp 2052	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/31678424/	yes [Km 19.7 uM]
BCRP 697	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/31678424/	yes

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P01EOR7	https://www.1pchem.com/search?query=1P01EOR7
AbovChem LLC	HY-16754
Chem Scene	CS-6470	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-6470
eMolecules	227979306	https://orderbb.emolecules.com/search/#?query=227979306
eMolecules	275100301	https://orderbb.emolecules.com/search/#?query=275100301
eMolecules	303941050	https://orderbb.emolecules.com/search/#?query=303941050
Hairui	SEXF014	http://www.hairuichem.com/en/product/search.do?q=SEXF014
MedChem Express	HY-16754	https://www.medchemexpress.com/search.html?q=HY-16754&ft=&fa=&fp=
Molnova	M11495	https://www.molnova.com/en/serch-list.html?keywords=M11495
MolPort	MolPort-046-417-160	https://www.molport.com/shop/molecule-link/MolPort-046-417-160
Selleck Chemicals	S8560	http://www.selleckchem.com/search.html?searchDTO.searchParam=S8560
ShangHai Biochempartner	BCP29404	http://www.biochempartner.com/search_BCP29404

PubMed

Title	Date	PubMed
A Dual-Administration Microtracer Technique to Characterize the Absorption, Distribution, Metabolism, and Excretion of [14 C]Seletalisib (UCB5857) in Healthy Subjects.	2017-12	28650526
Seletalisib: Characterization of a Novel, Potent, and Selective Inhibitor of PI3Kδ.	2017-06	28442583
First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases.	2017-05	28160012

Sample Use Guides

In Vivo Use Guide

The phase I, randomised, double-blind, placebo-controlled, single-centre studies (NCT02303509, NCT02207595) evaluated single and multiple oral doses of seletalisib (5-90 mg QD and 30 mg BID) in healthy adults and subjects with mild-to-moderate psoriasis (Study-1). Seletalisib was well tolerated at doses ≤15 mg (Study-1) and ≤45 mg QD (Study-2) for 14 days. No safety concerns or dose-limiting toxicities were identified (Study-1).

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 22:49:26 GMT 2025` Edited by `admin` on `Mon Mar 31 22:49:26 GMT 2025`
Record UNII	64CW205BDD
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

seletalisib [INN]

Preferred Name

English

SELETALISIB

Official Name

English

N-((R)-1-(8-CHLORO-2-(1-OXOPYRIDIN-3-YL)QUINOLIN-3-YL)-2,2,2-TRIFLUOROETHYL)PYRIDO(3,2-D)PYRIMIDIN-4-YLAMINE

Systematic Name

English

Seletalisib [WHO-DD]

Common Name

English

UCB-5857

Code

English

3-(8-CHLORO-3-((1R)-1-((PYRIDO(3,2-D)PYRIMIDIN-4-YL)AMINO)-2,2,2-TRIFLUOROETHYL)QUINOLIN-2-YL)PYRIDINE N-OXIDE

Systematic Name

English

UCB5857

Code

English

PYRIDO(3,2-D)PYRIMIDIN-4-AMINE, N-((1R)-1-(8-CHLORO-2-(1-OXIDO-3-PYRIDINYL)-3-QUINOLINYL)-2,2,2-TRIFLUOROETHYL)-

Systematic Name

English

Classification Tree Code System Code

EU-Orphan Drug

EU/3/18/1986